Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

11 Customer Reviews

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

    HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

  • U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NFG3eVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nBSFAuOTBizszN Mkf6NE01KGR? MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVj5eVByOjZ5MEK3PFQ>
HepG2 M3[0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHXRW4xNTFyIN88US=> NYLxO|dHOC12IHS= MlXGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXSyOlcxOjd6NB?=
HT29 NX\zZo5ZTnWwY4Tpc44hSXO|YYm= MoTIOVDDqG6P NWfXTFVnOjRvN{KgbC=> MnPybY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg NUP5SndKOjZ5MEK3PFQ>
HepG2 MnLNSpVv[3Srb36gRZN{[Xl? MmDlOVDDqG6P Mor5NlQuPzJiaB?= MXLpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFI1yqCqwrC= MlLGNlY4ODJ5OES=
HCC827 NWXH[ndET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUS1M|cvPS9zMDDuUS=> MYW3NuKhcA>? NGTXV|hFVVOR M4nUVYVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk M2PXbFI3Pjd3NEi0
A549  NE[1VW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O4d|ExNzF3L{KwJI5O MlfWO|LDqGh? NUnqXXNFTE2VTx?= Ml\1[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? NVT3Z4ZbOjZ4N{W0PFQ>
NCI-H460  NF;4[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu5NVAwOjBxM{Cgcm0> NYHrUocxPzMEoHi= MnHTSG1UVw>? Mojp[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? MVSyOlY4PTR6NB?=
J89GFP NVfORplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fKT2ROW00EoB?= NGDnZWtGSzVyPUS5Mlg2KMLzIEGyMlY2KG6P MkTLNlY2PjN3Nki=
THP89GFP Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPjSG1UV8Li NU[5XXNnTUN3ME2xPU4{PCEEsTC2MlQ{KG6P NXTQboNJOjZ3NkO1Olg>
SK-NEP-1 NVjBdFZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[3SFAvODIkgKOxNE4xKM7:TR?= MnPTNlQhcA>? MoPmSG1UV8Li M4LZTGlEPTB;N{[uN|Qhdk1? MXyyOlE4PjJzOR?=
G401 M2THNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuwNE4xOeLCk{GwMlAh|ryP NXW1ToR6OjRiaB?= MVPEUXNQyqB? MUXJR|UxRTF2Mz6wNkBvVQ>? NED5VpMzPjF5NkKxPS=>
SK-NEP-1 M1H5[2NmdGxiVnnhZoltcXS7IFHzd4F6 MVy1NEBvVQ>? NUS4[XRxOeLCk{Sg[C=> NVfVV2h{TE2VT9Mg MUXy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NY[0VI9MOjZzN{[yNVk>
G401 MnrFR4VtdCCYaXHibYxqfHliQYPzZZk> M3jrVFUxKG6P NITJTI0y6oDVNDDk MYTEUXNQyqB? Ml\JdoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MV2yOlE4PjJzOR?=
SK-NEP-1 NGPySHlCeG:ydH;zbZMhSXO|YYm= MnnTOVAwOTByIH7N NUP3S4JTOjRiaB?= MnXYSG1UV8Li M1rwUolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVv3SoU{OjZzN{[yNVk>
G401 M2TnWmFxd3C2b4Ppd{BCe3OjeR?= Mnq3OVAwOTByIH7N M3v5OVI1KGh? NXvxfIdZTE2VT9Mg MkTCbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{L1fVI3OTd4MkG5
SK-NEP-1 MVHGeY5kfGmxbjDBd5NigQ>? NUHwSGZjPTBxMUCwJI5O M1XxeFI1KGh? NF7CZYZFVVORwrC= MVTzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v NXjmRXRFOjZzN{[yNVk>
G401 NFHEPGlHfW6ldHnvckBCe3OjeR?= MV61NE8yODBibl2= Ml[5NlQhcA>? MlnZSG1UV8Li MofZd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? Ml35NlYyPzZ{MUm=
SK-NEP-1 M{O5T2Z2dmO2aX;uJGF{e2G7 M3zKPFUxNzFyMDDuUS=> NHn6RlkzPCCq NVPkcWh1TE2VT9Mg MVrpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> NHXVO3YzPjF5NkKxPS=>
G401 NUTUeIZFTnWwY4Tpc44hSXO|YYm= NFP1Zo42OC9zMECgcm0> MXuyOEBp M4LOVWROW00EoB?= MnfYbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> NW\2OY9sOjZzN{[yNVk>
RPMI 8226 MYfD[YxtKFO3co\peoFtKEG|c3H5 M4Xq[lIwPC94IH7N MVS0PQKBkWh? MWnpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp M4ez[FI3ODByMkmy
OPM2 MkX0R4VtdCCVdYL2bZZidCCDc4PhfS=> MUSyM|QwPiCwTR?= MljOOFjjiImq MoTxbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? NHvwc3gzPjByMEK5Ni=>
U266 NWPhd5U5S2WubDDTeZJ3cX[jbDDBd5NigQ>? Mn\2Nk81NzZibl2= MkLGOFjjiImq M1Phb4lv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NFXTRngzPjByMEK5Ni=>
H929 MYHD[YxtKFO3co\peoFtKEG|c3H5 MlXPNk81NzZibl2= NXfkZmtoPDkkgJno Mke4bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? M37aNVI3ODByMkmy
RPMI 8226  M13ieGFxd3C2b4Ppd{BCe3OjeR?= MUW05qCKdk1? M4[0OVI1NzR6IHi= NHi5O|ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M17Ue|I3ODByMkmy
HCC827 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xNEBvVQ>? NI[4clE1QCCq MmrkSG1UVw>? NGS5flBmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= MlPmNlU6PDR4MUe=
NCI-H23 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;vV5AzOTBibl2= MVG0PEBp NFqwUZVFVVOR M2jaXoVvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi MUOyOVk1PDZzNx?=
AML3 M3rrbGZ2dmO2aX;uJGF{e2G7 NV\oW2VXOC1zIN88US=> MUGyOOKhcA>? NYHXcFdicW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHe0d|YzPTZzMkm0NS=>
ML-1 MV7GeY5kfGmxbjDBd5NigQ>? NEnFV44xNTFizszN NV\LSld3OjUEoHi= NEHFTHdqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NEXHcYgzPTZzMkm0NS=>
RPMI-8226vr10  NYHzRVRKTnWwY4Tpc44hSXO|YYm= M2SxRVAuOSEQvF2= NFLmbJUzPMLiaB?= Mn3RbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmHWNlU3OTJ7NEG=
ML-1 MlnDSpVv[3Srb36gRZN{[Xl? NFnSUGoyKM7:TR?= M2mwU|I1yqCq M3S1SYlv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk NF;yOHczPTZzMkm0NS=>
RPMI-8226vr10  MlrtSpVv[3Srb36gRZN{[Xl? NFewR2kyKM7:TR?= MWCyOOKhcA>? MVnpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk M{HTNFI2PjF{OUSx
SK-N-BE (2) MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvLNlTjiImq Mm[3TWM2OD1zMESuNQKBkcLz4pEJO{45KG6P MnH4NlU{ODh7MU[=
SK-N-BE (2), PAN  MK NI\tW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjIT2xLOjUkgJno NIDOe2ZKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= NYSx[XBpOjV|MEi5NVY>
SK-N-BE (2), MK  PAN MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnG[Y4zPOLCiXi= MULJR|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P M4e4[FI2OzB6OUG2
SK-N-AS M4jZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjIOHAzPOLCiXi= MoH4TWM2OD1|Nz6x5qCKyrIkgJmyMlQhdk1? MUOyOVMxQDlzNh?=
SK-N-DZ MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr2NlTjiImq MnvmTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? MorpNlU{ODh7MU[=
Caki-1 NVXZbJNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PEVlExNzJ3L{WwJI5O M2LFOFQ5KGh? MUfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MlHTNlUzPzlzOUG=
ACHN NUnsNHhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq0eWJHOTBxMkWvOVAhdk1? MmTJOFghcA>? MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MlznNlUzPzlzOUG=
769-P MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjaRXAyOC9{NT:1NEBvVQ>? NEXYdpc1QCCq MmHNbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ M4rCd|I2Ojd7MUmx
786-O  NFnsboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLCU|EyOC9{NT:1NEBvVQ>? MkK2OFghcA>? MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? MmnKNlUzPzlzOUG=
Caki-1 NWHqWVV4SXCxcITvd4l{KEG|c3H5 M4L5Z|UxKG6P Mmj5OFghcA>? MV7pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MWSyOVI4QTF7MR?=
ACHN MVvBdI9xfG:|aYOgRZN{[Xl? NYrjfooxPTBibl2= MWC0PEBp M3q0OIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ M4XINFI2Ojd7MUmx
769-P NIe3SYZCeG:ydH;zbZMhSXO|YYm= NVnx[|h5PTBibl2= MmrUOFghcA>? Mn\jbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? M3[zNFI2Ojd7MUmx
786-O  NEHFbXVCeG:ydH;zbZMhSXO|YYm= MVu1NEBvVQ>? NIDncXc1QCCq MYfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MkHhNlUzPzlzOUG=
Caki-1 NUjnenVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn0NplLOjVxNUCgcm0> M{SybFQ5KGh? NHzSboJFVVOR NFjzXlNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni M3HKflI2OTd4M{W0
ACHN MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nDe|I2NzVyIH7N M1zVO|Q5KGh? MofkSG1UVw>? MnjBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= MYqyOVE4PjN3NB?=
769-P MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiyOU82OCCwTR?= NGWySJQ1QCCq M3TpOmROW09? MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MUOyOVE4PjN3NB?=
Caki-1 MX3Dc4xwdnliRn;ycYF1cW:wIFHzd4F6 NXfGd3FnPTBibl2= NGTnVXM4NTF2IHS= Ml\iSG1UVw>? NWfscItEe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? Mn3FNlUyPzZ|NUS=
ACHN MnXGR49td267IF\vdo1ifGmxbjDBd5NigQ>? NGXwfnc2OCCwTR?= MXG3MVE1KGR? NH\vTXVFVVOR Mon2d5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MUWyOVE4PjN3NB?=
769-P MkLJR49td267IF\vdo1ifGmxbjDBd5NigQ>? Mon0OVAhdk1? NIGyZ5A4NTF2IHS= M3Xhc2ROW09? MXzzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> Mn20NlUyPzZ|NUS=
Caki-1 NU\4Xo97SXCxcITvd4l{KEG|c3H5 NEewWJo2OCCwTR?= NFzyVVU1QCCq M363OmROW09? NIHSOGpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NInKd5YzPTF5NkO1OC=>
ACHN MoC2RZBweHSxc3nzJGF{e2G7 M1OxOFUxKG6P NXPEO3JOPDhiaB?= MVTEUXNQ MWPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3PD[lI2OTd4M{W0
769-P M2TaR2Fxd3C2b4Ppd{BCe3OjeR?= NVPPbFUyPTBibl2= M2DUXVQ5KGh? M1;DZmROW09? Ml\ObY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWrkN5RKOjVzN{[zOVQ>
MDA-MB-231 NWrzPWx4VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 NXKyT5UyOTEEoH7N MWCzxsBl NWW1cpp1TE2VTx?= NVLabIpI[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg M1XYOlI1QDFyNEm3
BT-549 M{HZVG1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? M4jpTFExyqCwTR?= NXTNRoNHO8LiZB?= NIPIfY5FVVOR M1LPUoFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= NFHVeXEzPDhzMES5Oy=>
MCF-7  NYm5[ld2VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 M2XRdFExyqCwTR?= NV73eYlJO8LiZB?= NVr1PG5lTE2VTx?= NYXyPJJR[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MWOyOFgyODR7Nx?=
MCF-7 NUTl[odOTnWwY4Tpc44hSXO|YYm= MVO1MVUxKG6P MYSyOEBp MYrEUXNQ MmjwdoVlfWOnZDD0bIUhdGW4ZXygc4Yh\XiycnXzd4lwdiCxZjDFVu6yNCCSUjDhcoQhTm:6QUJCpC=> NVvxNpE4OjR|Nk[0NFc>
CTS NXzKb5dCSXCxcITvd4l{KEG|c3H5 MV[w5qCUPDBibl5CpC=> NWfId|BGPDhiaB?= NUO5RnNkcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mo\UNlQzPDR2Mkm=
OCI-AML3  MmjYRZBweHSxc3nzJGF{e2G7 NFrZT2ox6oDVNECgcm3DqA>? MWO0PEBp M170bolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFnVVIYzPDJ2NESyPS=>
U937 M3ThS2Fxd3C2b4Ppd{BCe3OjeR?= M{fadlDjiJN2MDDuUeKh MWO0PEBp M2jOXolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWSyOFI1PDR{OR?=
PC3 MYDBdI9xfG:|aYOgRZN{[Xl? MVywMVExOCCwTR?= NIjPZ4wzPC92ODDo M17xPIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXyyOFE3OzJ|MB?=
PC3-AR M2C0NmFxd3C2b4Ppd{BCe3OjeR?= NYrxZ45WOC1zMECgcm0> NIPFfZQzPC92ODDo NIPuOW5qdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWW0XW9oOjRzNkOyN|A>
PC3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGwMVExOCCwTR?= M1PV[|I1NzR6IHi= NVLHXlN6cW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?= NWPucmxjOjRzNkOyN|A>
PC3-AR NUDTdW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLzeJU6OC1zMECgcm0> M{fiflI1NzR6IHi= NWrZbZBGcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS|JOKHCqYYPl MonrNlQyPjN{M{C=
PC3 M1TPdWZ2dmO2aX;uJGF{e2G7 M1rieFAuOTByIH7N NFq3T3AzPCCq Mk\Md5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= M2[4clI1OTZ|MkOw
PC3-AR M3LQS2Z2dmO2aX;uJGF{e2G7 NX\0eFlwOC1zMECgcm0> MlTONlQhcA>? NFLlfW9{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> MVGyOFE3OzJ|MB?=
OS-RC-2 Mny0R4VtdCCYaXHibYxqfHliQYPzZZk> MYSwMVExODBibl2= Moe3NlQwPDhxN{KgbC=> M3faNGROW09? MmTn[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYrMdlhyOjRzNES3N|c>
OS-RC-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPFOVAhdk1? NH;qTZI1QCCq NEDkVHVFVVOR Ml3hbY5lfWOnczDHNk9OKGG{cnXzeC=> NXPoZVZiOjRzNES3N|c>
OS-RC-2 NVrvWWJYSXCxcITvd4l{KEG|c3H5 NU\2TIpFPTBibl2= Ml;VOFghcA>? M3K4bmROW09? NWTRdmRPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MUiyOFE1PDd|Nx?=
SK-N-AS M1TNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG4S2Yx6oDVOECgcm0> MWi0PEBp NYXXT45PUUN3ME2yO{41KG6P Mo[2NlQxQTh5OUm=
SK-N-DZ MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyw5qCUQDBibl2= NXvnSZpZPDhiaB?= NFTafoZKSzVyPUKxMlkhdk1? MUmyOFA6QDd7OR?=
SK-N-SH M3Xvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf3Xocx6oDVOECgcm0> MWS0PEBp MlPTTWM2OD15Mj6zJI5O M1Lm[lI1ODl6N{m5
SK-N-BE MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH6b4pjOOLCk{iwJI5O NHHKUpM1QCCq MofzTWM2OD15NT60JI5O NF7WTGIzPDB7OEe5PS=>
SK-N-AS NITL[JZCeG:ydH;zbZMhSXO|YYm= M1XobFDjiJN6MDDuUS=> MV[0PEBp NFHzeWlxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> M4fmU|I1ODl6N{m5
SK-N-DZ Mn\PRZBweHSxc3nzJGF{e2G7 NF:3cFcx6oDVOECgcm0> MUC0PEBp NVXFfpVreG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NVHrVHZ1OjRyOUi3PVk>
SK-N-SH NVOwTVZGSXCxcITvd4l{KEG|c3H5 MW[w5qCUPDBibl2= M1qzblQ5KGh? MYfwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= M1X4blI1ODl6N{m5
SK-N-BE M4C4OmFxd3C2b4Ppd{BCe3OjeR?= M17rclDjiJN2MDDuUS=> MXe0PEBp MlHUdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NVzUNYY6OjRyOUi3PVk>
SK-N-AS MUTGeY5kfGmxbjDBd5NigQ>? MViw5qCUQDBibl2= M4fWdlQ5KGh? MXTpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ MUWyOFA6QDd7OR?=
SK-N-DZ NV7v[INGTnWwY4Tpc44hSXO|YYm= M3LMT|DjiJN6MDDuUS=> M1fZc|Q5KGh? NUTve5h6cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MlG1NlQxQTh5OUm=
SK-N-SH Ml23SpVv[3Srb36gRZN{[Xl? MorDNQKBmzRyIH7N NYrKXXRpPDhiaB?= MlXnbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NFH6OHozPDB7OEe5PS=>
SK-N-BE Mmj4SpVv[3Srb36gRZN{[Xl? M1jpVlDjiJN2MDDuUS=> NXK4V4N4PDhiaB?= NXjjRpBDcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MnvtNlQxQTh5OUm=
HCC-LM3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICzT2gyNTFyMECgcm0> Mk\2NlQwPDhxN{KgbC=> NEP4VmJFVVOR MmqzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MojXNlQxQTN7NU[=
HepG2 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfC[48yNTFyMECgcm0> NFLwUGYzPC92OD:3NkBp M3rUN2ROW09? M4LJ[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlTRNlQxQTN7NU[=
SMMC-7721 NGXoU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP0NU0yODByIH7N MlK1NlQwPDhxN{KgbC=> M3zRRWROW09? M3nmeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NG\0SZUzPDB7M{m1Oi=>
HCC-LM3 M2LmOWFxd3C2b4Ppd{BCe3OjeR?= NF;sOFk2OCCwTR?= NFfXRlc1QCCq NYOyc4FyTE2VTx?= M2PCW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NUj2e4RiOjRyOUO5OVY>
HepG2 MmO5RZBweHSxc3nzJGF{e2G7 MYW1NEBvVQ>? MkLpOFghcA>? MUjEUXNQ MVzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> NITBdFkzPDB7M{m1Oi=>
SMMC-7721 NGjqS5ZCeG:ydH;zbZMhSXO|YYm= Mn[5OVAhdk1? NUjRdmlTPDhiaB?= MYnEUXNQ M2LOcolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MnHBNlQxQTN7NU[=
HCC-LM3 MkLlSpVv[3Srb36gRZN{[Xl? MmDFOVAwOTByIH7N M2rNb|I1KGh? NFL0SFRFVVOR NXXqPGEz\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> M3y3WFI1ODl|OUW2
HepG2 NET1SoVHfW6ldHnvckBCe3OjeR?= MnXUOVAwOTByIH7N MX:yOEBp NX22WWpTTE2VTx?= MWTk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi M1HOXlI1ODl|OUW2
SMMC-7721 MX\GeY5kfGmxbjDBd5NigQ>? M2Dwd|UxNzFyMDDuUS=> MkTpNlQhcA>? MWjEUXNQ Mkfh[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= NFrGRXkzPDB7M{m1Oi=>
HCC-LM3 NWL2WZdUTnWwY4Tpc44hSXO|YYm= M3rsUFUxNzFyMDDuUS=> M3fBeFI1KGh? NYrYZXNtTE2VTx?= MkS3[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? MVuyOFA6Ozl3Nh?=
HepG2 M{PaR2Z2dmO2aX;uJGF{e2G7 MlzFOVAwOTByIH7N M{DtRlI1KGh? NUnTZldGTE2VTx?= NUDpO4w3\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MW[yOFA6Ozl3Nh?=
SMMC-7721 M2\rVmZ2dmO2aX;uJGF{e2G7 Mn;VOVAwOTByIH7N M2fLWlI1KGh? MVHEUXNQ M1HV[oRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? MUCyOFA6Ozl3Nh?=
FaDu NHnkfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f5OVExOOLChX7N MkHRPE8yOC9zMjDo NUDYTXdz\Gm|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl NHftWW4zPDB{NkS4Ni=>
FaDu MYnGeY5kfGmxbjDBd5NigQ>? M3j5SFExOOLChX7N MlfSNk81NzhxMUKgbC=> MWXpcoR2[2WmIICyNXdi\jFxQ3nwNeKh\XiycnXzd4lwdg>? M4[2N|I1ODJ4NEiy
PC-3  Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn5flAxNTFyIN88US=> MWmyOE81QC95MjDo NGryUHNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{PRdVI{QTlzMkG2
LNCaP Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\jXlAuPSEQvF2= MWiyOE81QC95MjDo MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGnVXlAzOzl7MUKxOi=>
RWPE-1  NHXzS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XafVAuOjBizszN NGrNSpUzPC92OD:3NkBp MorYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUDL[4dHOjN7OUGyNVY>
Capan-1 NX7ZOlF7TnWwY4Tpc44hSXO|YYm= MXqyOU82OC9zMECgcm0> NHjON2g5NzJ2L{S4JIg> NYnxZ3pUTE2VTx?= MVfkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MVOyN|kzOjh6Nh?=
L3.6pl NH7hVHNHfW6ldHnvckBCe3OjeR?= NVOzOZdrOjVxNUCvNVAxKG6P MX24M|I1NzR6IHi= MXLEUXNQ MmfS[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MlfzNlM6OjJ6OE[=
CFPAC-1  MUPGeY5kfGmxbjDBd5NigQ>? NX3rT3ZQOjVxNUCvNVAxKG6P MX64M|I1NzR6IHi= Ml7FSG1UVw>? NXrr[lly\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> Mn7DNlM6OjJ6OE[=
Capan-1 M3PCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\TNlUwPTBxMUCwJI5O MWm0PEBp MVvEUXNQ NFTYfHpz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{LXelI{QTJ{OEi2
L3.6pl NHq5NFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjkSYczPS93MD:xNFAhdk1? MmnFOFghcA>? MonTSG1UVw>? NVvZVGhmemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHrjPZMzOzl{Mki4Oi=>
CFPAC-1  M1[2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\FNlUwPTBxMUCwJI5O MlT5OFghcA>? MnHZSG1UVw>? NYO2cWxZemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUCyN|kzOjh6Nh?=
Capan-1 MWnBdI9xfG:|aYOgRZN{[Xl? MlW0NlUwPTBxMUCwJI5O MYS0PEBp NFLTbVRFVVOR NV;T[2RbcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVy2Xpg5OjN7MkK4PFY>
L3.6pl NUPHRXZkSXCxcITvd4l{KEG|c3H5 M2Sxc|I2NzVyL{GwNEBvVQ>? M2nXNVQ5KGh? MUPEUXNQ MmLxbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4DhbVI{QTJ{OEi2
CFPAC-1  NXPzUG54SXCxcITvd4l{KEG|c3H5 MlzFNlUwPTBxMUCwJI5O MljZOFghcA>? M4TjTWROW09? MXHpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mmn0NlM6OjJ6OE[=
HN22 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjaUlMxNTJyIH7N NEPMVo0zPC92ODDo NXf5bHRWTE2VTx?= NUTseIducW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NX3kXnJ3OjN6N{eyN|U>
HSC4  NHrOUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHDVHBNOC1{MDDuUS=> M2\Cb|I1NzR6IHi= MnPISG1UVw>? NIjUW3RqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz M4jsTVI{QDd5MkO1
HN22 MXPBdI9xfG:|aYOgRZN{[Xl? MVmwMVIxKG6P NFiyNFM1QCCq MVXEUXNQ MXvpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUiyN|g4PzJ|NR?=
HSC4  NHzj[5lCeG:ydH;zbZMhSXO|YYm= M{nVVFAuOjBibl2= MkXTOFghcA>? MknmSG1UVw>? NV:1NYltcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXn5U5FOOjN6N{eyN|U>
HN22 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvJNE0zOCCwTR?= M{jTOFQ5KGh? MoHRSG1UVw>? MXTpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= MnTxNlM5Pzd{M{W=
HSC4  Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLiNE0zOCCwTR?= NXnFPVcyPDhiaB?= M1rXNWROW09? NH\zVY9qdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA> M{DGNVI{QDd5MkO1
HN22 MlLpSpVv[3Srb36gRZN{[Xl? MVSwMVIxKG6P NH7ES3M1QCCq NF3NXG9FVVOR NHzZN3h{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> MoTVNlM5Pzd{M{W=
HSC4  NF7q[3JHfW6ldHnvckBCe3OjeR?= MX:wMVIxKG6P NVfyclFKPDhiaB?= NEXLUZpFVVOR M2mxd5N2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> NIHBUFIzOzh5N{KzOS=>
Cal62 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:zbo1KSzVyPUOzJOKyKDRibl2= M1rDOVI{QDJ2ME[0
Hth7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vQNGlEPTB;MUWgxtEhOiCwTR?= MYKyN|gzPDB4NB?=
Hth83 NYTGd|VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[xOVZKSzVyPUO0JOKyKDVibl2= MmrXNlM5OjRyNkS=
C643 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELldGZKSzVyPUexJOKyKDFyIH7N MlfiNlM5OjRyNkS=
SW1736 NXX4[GJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTN3INMxJFghdk1? MkfWNlM5OjRyNkS=
T241 M1n6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjZRpQ5UUN3ME22OUDDuSB5IH7N Mn\SNlM5OjRyNkS=
T351 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTme|hWUUN3ME21NEDDuSBzMDDuUS=> MWeyN|gzPDB4NB?=
BHP2-7 NVrSPIQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor3TWM2OD1|NzFCtUA3KG6P MkLqNlM5OjRyNkS=
T238 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV73UpZ3UUN3ME2xMFUxOCEEsTCyNFAhdk1? NU\2bWFQOjN6MkSwOlQ>
HCT8 M1yxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq1VWE4OiCq NX\jWGdzTE2VTx?= M4fSbGlEPTB;MUKuPgKBkcLz4pEJNU46KG6P Mli5NlMzQTl|OEi=
H630 NEjvO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXsO|IhcA>? MoG5SG1UVw>? NVv5bo9qUUN3ME2xNk416oDLwsJihKk{NjFibl2= NGW1bnUzOzJ7OUO4PC=>
cH630 5-FU-res MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWO3NkBp NHLmXWpFVVOR MXnJR|UxRTF3LkZihKnDueLCiUGuNkBvVQ>? M2rVZ|I{Ojl7M{i4
HCT116 M{TWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XVVFczKGh? NILIPYRFVVOR NHLHV3dKSzVyPUGwMlfjiIoEsfMAjVIvOiCwTR?= NWK4O5RtOjN{OUmzPFg>
HCT116 p53−/− Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rYV|czKGh? MUPEUXNQ NUfVZ4xOUUN3ME24MlbjiIoEsfMAjVEvPyCwTR?= MXeyN|I6QTN6OB?=
dHCT116 p21−/− NGLpZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWW3NkBp NYf6[3U6TE2VTx?= MonzTWM2OD13LkpihKnDueLCiUGuN{BvVQ>? M3:2TVI{Ojl7M{i4
HT29 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPVO|IhcA>? MVLEUXNQ M2jYNmlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P M4e2WlI{Ojl7M{i4
LoVo M{nncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PLTlczKGh? M1XOV2ROW09? MX3JR|UxRTVwMfMAjeKy6oDLMD62JI5O Mm\JNlMzQTl|OEi=
RKO NUP2[5RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXG3NkBp NGXnT25FVVOR M{CwOWlEPTB;Nz655qCKyrIkgJmyMlIhdk1? NXzZRZRtOjN{OUmzPFg>
SW480 M1jI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS3NkBp NFyxOpNFVVOR MVXJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? MVqyN|I6QTN6OB?=
eSW620 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7NUotEPzJiaB?= MnL3SG1UVw>? M4XncGlEPTB;OT6x5qCKyrIkgJmyMlEhdk1? M3nWTlI{Ojl7M{i4

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen April 30, 2017 Phase 1|Phase 2
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT02890069 Recruiting Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer Novartis Pharmaceuticals|Novartis October 26, 2016 Phase 1
NCT01802879 Active, not recruiting Hematologic Neoplasms Novartis Pharmaceuticals|Novartis June 24, 2013 Phase 2
NCT00532675 Active, not recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 22, 2008 Phase 1
NCT02961816 Not yet recruiting Lymphoma M.D. Anderson Cancer Center February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

Related Antibodies

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID